OXCARP 600 mg Injection/Intraarticular

What is OXCARP 600 mg

OXCARP 600 mg is an injectable form of Oxcarbazepine, a second-generation antiepileptic drug (AED) used primarily in the management of partial seizures and generalized tonic-clonic seizures. While oral formulations are more common, this injectable form is designed for clinical scenarios where oral administration is not feasible — such as in acute care settings, for patients with swallowing difficulties, or when rapid onset is needed. It is presented in a pack size of 50 syringes (10 per blister, 5 blisters), indicating hospital-grade usage.

• Generic Name: Oxcarbazepine
• Brand Name: OXCARP 600 mg
• Form: Injection/Intraarticular
• Indications:
  • Monotherapy or adjunctive therapy in partial seizures
  • Management of generalized tonic-clonic seizures
  • Potential use in neuropathic pain (off-label)
• Pharmaceutical Class: Dibenzazepine anticonvulsant
• Target Patients: Adults and children with epilepsy requiring parenteral treatment

How to use OXCARP 600 mg

OXCARP 600 mg injection should be administered by qualified healthcare personnel under strict aseptic conditions, either intravenously or potentially intraarticularly depending on the clinical protocol and product labeling. Its use should align with the individual patient’s therapeutic goals, renal function, and seizure profile.

• Administration Route:
  • Intravenous infusion is most common for injectable forms.
  • Intraarticular usage is investigational or specific to off-label use and pain management protocols.
• Preparation:
  • Inspect the solution for clarity and absence of particulates.
  • Do not use if the solution appears discolored or precipitated.
• Infusion Instructions:
  • Administer over a specified duration to prevent local irritation.
  • Use an infusion pump or gravity drip based on institutional guidelines.
• Precautions:
  • Do not mix with incompatible drugs in the same IV line.
  • Monitor for signs of allergic reaction or extravasation.
• Monitoring Requirements:
  • Monitor serum sodium levels (risk of hyponatremia).
  • Check renal and hepatic function periodically.
  • Evaluate patient for neurological and dermatological side effects.

Mode of Action OXCARP 600 mg

Oxcarbazepine functions by modulating the activity of sodium channels in the brain. Once administered, it is quickly metabolized to its active form, the 10-monohydroxy derivative (MHD), which is responsible for its therapeutic action.

• Neuronal Mechanism:
  • Blocks voltage-gated sodium channels, stabilizing neuronal membranes.
  • Reduces repetitive neuronal firing by suppressing synaptic transmission in epileptic foci.
  • Modulates high-voltage activated calcium channels (minor role).
• Clinical Outcomes:
  • Reduces the frequency and severity of partial and generalized seizures.
  • May improve mood and reduce neuropathic pain (off-label).
• Pharmacokinetics:
  • Converted hepatically to MHD, its primary active metabolite.
  • MHD has a half-life of 8–10 hours, allowing for twice-daily dosing.
  • Renally excreted; dosage adjustment is required in renal impairment.

OXCARP 600 mg Interactions OXCARP 600 mg

OXCARP 600 mg interacts with various medications through enzyme induction and pharmacodynamic synergism or antagonism. Close monitoring and dosage adjustments are necessary when used with other drugs.

• Enzyme Induction:
  • Induces CYP3A4 and CYP3A5 enzymes, affecting metabolism of many drugs.
  • Decreases effectiveness of hormonal contraceptives — recommend alternative birth control.
• Drugs Affected:
  • Antiepileptics: May increase levels of phenytoin; may reduce lamotrigine levels.
  • Calcium Channel Blockers: Reduced efficacy due to enzyme induction.
  • SSRIs/TCAs: Monitor for mood-related changes; additive CNS effects may occur.
• Electrolyte Balance:
  • Increased risk of hyponatremia with diuretics (e.g., hydrochlorothiazide, furosemide).
• Alcohol and Sedatives:
  • Enhanced CNS depressant effects; avoid concurrent use.

Dosage of OXCARP 600 mg

The dosage of OXCARP 600 mg injection should be individualized based on age, weight, renal function, and clinical response. This formulation allows flexible use in titration schedules, particularly in acute settings.

• Adults:
  • Initial dose: 600 mg per day in 1 or 2 divided doses.
  • Titrate by 300–600 mg/day increments at weekly intervals.
  • Maintenance range: 900–2400 mg/day in divided doses.
• Pediatrics (≥6 years):
  • Initial: 8–10 mg/kg/day divided twice daily.
  • Maximum: ~60 mg/kg/day based on tolerability and seizure control.
• Renal Impairment:
  • For CrCl <30 mL/min: Initiate at 50% of standard dose.
  • Monitor therapeutic response and adjust accordingly.
• Hepatic Impairment:
  • No initial adjustment in mild/moderate impairment.
  • Use with caution in severe hepatic dysfunction.

Possible side effects of OXCARP 600 mg

Like all antiepileptic drugs, OXCARP 600 mg may cause both common and serious side effects. Patients should be counseled and monitored regularly for signs of intolerance or toxicity.

• Common Side Effects:
  • Dizziness, drowsiness
  • Double vision (diplopia)
  • Nausea, vomiting
  • Fatigue, tremor
  • Balance difficulties (ataxia)
• Serious Side Effects:
  • Hyponatremia: May lead to confusion, seizures, coma
  • Dermatologic Reactions: SJS/TEN — immediate discontinuation required
  • Hepatic Dysfunction: Elevated liver enzymes, jaundice
  • Blood Dyscrasias: Leukopenia, thrombocytopenia (rare)
• Psychiatric Effects:
  • Depression, mood swings
  • Suicidal ideation (requires immediate intervention)

OXCARP 600 mg Contraindications OXCARP 600 mg

OXCARP 600 mg is contraindicated in certain medical conditions and patient populations where its use could pose significant risks.

• Known Hypersensitivity:
  • To Oxcarbazepine or any formulation components.
  • Cross-reactivity with carbamazepine in ~25% of patients.
• History of Severe Skin Reactions:
  • Patients with prior SJS, TEN, or DRESS syndrome.
• Cardiac Conditions:
  • Patients with second- or third-degree AV block (may affect conduction).
• Severe Hepatic Impairment:
  • Use cautiously or avoid due to altered drug metabolism.

Storage of OXCARP 600 mg

Proper storage of OXCARP 600 mg is critical to preserve its stability, sterility, and therapeutic efficacy.

• Storage Temperature:
  • Maintain between 2°C and 8°C (refrigerated conditions).
  • Avoid freezing — can compromise formulation integrity.
• Packaging:
  • Keep in original blister packs until use to protect from light and contamination.
• Shelf Life:
  • Refer to product label for expiration date.
  • Do not use after expiry, even if visually intact.
• After Opening:
  • Use immediately once the vial or syringe is opened.
  • Discard any unused portion to prevent contamination.